CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and In Vitro Experiments

Figure 5

Pathway enrichment of CYP26A1. Notes: (a) GSEA analysis of CYP26A1; (b) Western blot indicated that CYP26A1 could partly activate the EMT pathway.

(a)

(b)